Abstract | BACKGROUND AND OBJECTIVES: DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was an open-label, dosage-titration study. Patients with serum phosphorus > or =5.5 mg/dl were enrolled (n = 46). Sevelamer carbonate was administered for 8 wk. Patients were supplemented with native vitamin D (400 IU). The primary efficacy parameter was the change from baseline in serum phosphorous. Secondary measures included the percentage of serum phosphorus responders; changes in serum lipids, calcium- phosphorus product, and bicarbonate; and safety and tolerability. RESULTS: CONCLUSIONS:
|
Authors | Markus Ketteler, Marianne Rix, Stanley Fan, Nicholas Pritchard, Ove Oestergaard, Scott Chasan-Taber, Jeremy Heaton, Ajay Duggal, Philip A Kalra |
Journal | Clinical journal of the American Society of Nephrology : CJASN
(Clin J Am Soc Nephrol)
Vol. 3
Issue 4
Pg. 1125-30
(Jul 2008)
ISSN: 1555-905X [Electronic] United States |
PMID | 18450923
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Bicarbonates
- Biomarkers
- Chelating Agents
- Cholesterol, LDL
- Polyamines
- Vitamins
- Vitamin D
- Phosphorus
- Sevelamer
- Calcium
|
Topics |
- Aged
- Australia
- Bicarbonates
(blood)
- Biomarkers
(blood)
- Calcium
(blood)
- Chelating Agents
(adverse effects, therapeutic use)
- Cholesterol, LDL
(blood)
- Chronic Disease
- Down-Regulation
- Europe
- Female
- Humans
- Hyperphosphatemia
(blood, drug therapy, etiology)
- Kidney Diseases
(blood, complications, drug therapy)
- Male
- Middle Aged
- Phosphorus
(blood)
- Polyamines
(adverse effects, therapeutic use)
- Renal Dialysis
- Sevelamer
- Severity of Illness Index
- Time Factors
- Treatment Outcome
- Vitamin D
(therapeutic use)
- Vitamins
(therapeutic use)
|